Skip Navigation

Visiting Dana-Farber? See our prescreening and mask requirements.

About the Chen-Huang Center for EGFR-Mutant Lung Cancers

  • Pasi Jänne, MD, PhD, Director of the Chen-Huang Center for EGFR-Mutant Lung Cancers

    Pasi Jänne, MD, PhD, Director of the Chen-Huang Center for EGFR-Mutant Lung Cancers


  • Mission and Goals

    Lung cancer remains the most common cause of cancer-related deaths in the United States for both men and women. Epidermal growth factor receptor (EGFR) mutations are found in 15 percent of lung cancer patients in the United States and European Union, and in 50 percent of lung cancer patients in Asia.


  • About the Chen-Huang Center for EGFR Mutant Lung Cancers
    Pasi Jänne, MD, PhD, Director of the Chen-Huang Center for EGFR-Mutant Lung Cancers, describes how the Center will support and care for patients with epidermal growth factor receptor (EGFR)-mutant lung cancers.


  • Leading the Way

    In 2004, Dana-Farber investigators discovered that a subset of lung cancers exhibited mutations in the EGFR gene. These mutations were predictive of the clinical efficacy of EGFR kinase inhibitors. This discovery was one of the first examples of precision medicine for lung cancer and helped catalyze the entire field of precision medicine for patients with lung cancer.

    Dana-Farber became one of the first American centers to begin routine clinical testing for EGFR mutations — which is now the standard of care worldwide. EGFR inhibitors are now used as the initial systemic therapy (instead of chemotherapy) for newly diagnosed patients with advanced EGFR-mutant lung cancers.

    Living with EGFR-Mutant Lung Cancer? You're not alone!

    Check back for the dates to our next 4-session virtual course, in which you'll learn to:

    • Restore balance, connection, and calm
    • Develop clear, concise questions for your oncology team
    • Generate and communicate personalized solutions
    • Learn quick, easy, portable relaxation techniques
    • Enhance your social support
    • Reduce physical and emotional symptoms
    • Help manage stress
    • Develop coping skills

    Our Mission

    As part of Dana-Farber's Thoracic (Lung) Cancer Treatment Center, the Chen-Huang Center for EGFR-Mutant Lung Cancers will push the boundaries of knowledge in treating lung cancer, to develop new and better therapies. The mission of the Center is to improve the lives of patients with EGFR-mutant lung cancer through innovative research and cutting edge clinical care. This will be accomplished through the seamless integration of preclinical, translational, and clinical research, including:

    • New and novel clinical trials for patients with EGFR-mutant lung cancers
    • Translational studies of EGFR-mutant lung cancers to ultimately help refine therapeutic approaches for patients
    • Discovery studies that focus on the generation of research models
    • Education, training, and knowledge exchange opportunities for clinicians, researchers, and trainees from the U.S. and around the world, focusing on EGFR-mutant lung cancers

    About Winston Chen and Phyllis Huang

    The Chen-Huang Center was established with a $5 million gift from Winston Chen, PhD, and his wife, Phyllis Huang, to stimulate research, promote clinical trials, and strengthen Dana-Farber's capabilities for studying and treating EGFR-mutant lung cancer.

    For many years, the couple's family foundation, the Paramitas Foundation, focused on supporting higher education. Their recent funding has shifted to health care projects, specifically lung cancer care and research led by Pasi Jänne, MD, PhD, director of the Carole M. and Philip L. Lowe Center for Thoracic Oncology, and director of the Robert and Renée Belfer Center for Applied Cancer Science at Dana-Farber.

    "Phyllis and I hope our gift will bring much needed attention to lung cancer and will illustrate how vital financial support is for making discoveries," said Chen. "We support Dr. Jänne and Dana-Farber because of their impressive centers, research facilities, and the discoveries they are making every day."

    Learn how you can help support the work of this Center.


  • More Information on the Chen-Huang Center for EGFR-Mutant Lung Cancers

    Press release announcing the Chen-Huang Center

    Boston Herald's feature story about the Chen-Huang Center

    Hear from a patient treated for EGFR-mutant lung cancer

  • Chen-Huang Center for EGFR-Mutant Lung Cancers logo
  • New Patient Appointments
    877-442-3324

    Make Appointment Online
    Dana-Farber Brigham Cancer Center logo
    US News adult badge - smaller

  • Living with EGFR-Mutant Lung Cancer Patient Forum

    Please join the Chen-Huang Center for EGFR-Mutant Lung Cancers for the third annual "Living with EGFR-Mutant Lung Cancer" forum on Wednesday, May 17. During this virtual event, we will discuss information about EGFR-mutant lung cancer, research advances, symptom management, integrative and radiation therapy, as well as hear from our patients and caregivers.

    Information and registration

  • Second Annual “Living with EGFR-Mutant Lung Cancer: A Virtual Forum for Patients and Caregivers” (May 25, 2022)
    During this event we discussed information about EGFR-mutant lung cancer, research advances, symptom management, as well as hearing from our patients and caregivers.

  • A Patient's Journey with EGFR Mutant Lung Cancer
    A triathlete shares her powerful journey fighting EGFR-mutant lung cancer. And Pasi Jänne, MD, PhD, director of the Lowe Center for Thoracic Oncology and the Chen-Huang Center for EGFR-Mutant Lung Cancers, details the latest research into this disease.

  • EGFR-Mutant Lung Cancer: A Patient's Journey
    Dana-Farber patient Laura Eastment shares her treatment journey with epidermal growth factor receptor (EGFR) mutant lung cancer.

  • 2021 Living with EGFR-Mutant Lung Cancer: A Virtual Forum for Patients and Caregivers
    View the May 2021 patient and caregiver forum hosted by the Chen-Huang Center for EGFR-Mutant Lung Cancers.